DOCSLIB.ORG

What's Going on Down There?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What's Going on Down There? What’s Going on Down There? Denise Rizzolo, PhD, PA-C Introduction • Vulvovaginitis is inflammation of the vulva and vaginal tissues. • Characterized by vaginal discharge and/or vulvar itching and irritation as well as possible vaginal odor. • Accounts for 10 million visits yearly in the US and is the most common gynecologic complaint in prepubertal girls. History- What should you ask? • Pruritus -General or just one spot • Soreness: stinging / burning / pain • Difficulty with sex • Lumps • Discharge • Partner’s have any symptoms • History of similar symptoms Physical Examination • Careful gynecologic exam • Inspection of discharge • Close examination of vulvovaginal area • Careful inspection of cervix • Look at perineum as well Physiologic Discharge • Responsible for 10 percent of cases of vaginal discharge. • Composed of vaginal squamous cells suspended in fluid medium. • Clinical characteristics: • clear to slightly cloudy • non-homogeneous • highly viscous • Changes throughout the month Normal Vaginal Discharge • Not associated with: • itching • burning • malodor • Normal increase in volume • ovulation • following coitus • after menses • during pregnancy The Big 3 •Three most common causes of vulvovaginitis include: • Bacterial Vaginosis • Vaginal candidiasis • Trichomonas Vaginalis •Others include: atrophic vaginitis, irritant vaginitis, and other STIs. Vaginal Candidiasis- Overview • Less common in postmenopausal women, unless taking estrogen. • 90% of yeast infections are secondary to Candida Albican (Most common). • Risk Factors include: • Pregnancy • Oral contraceptives • Uncontrolled DM • Recent antibiotic use • Discussing around tight underwear, cotton underwear, spandex • Literature has been mixed to support this theory. Vaginal Candidiasis- Signs and Symptoms Patient Reports Physical Exam • The discharge varies from • Whitish cottage cheese watery to thick cottage cheese discharge discharge • Vulvar erythema and edema • Vaginal soreness • Vaginal erythema • Dyspareunia • Severe vaginal itching • External dysuria Vaginal Candidiasis- Diagnosis • Normal pH4-4.5 • Positive results on microscopic exam (yeast buds and pseudohyphae) • Culture if unsure Vaginal Candidiasis- Treatment • The topically applied azole drugs are more effective than nystatin (CDC) • Butoconazole 2% cream (single dose bioadhesive product), 5 g intravaginally in a single application OR • Terconazole 0.4% cream 5 g intravaginally daily for 7 days OR • Terconazole 0.8% cream 5 g intravaginally daily for 3 days OR • Terconazole 80 mg vaginal suppository, one suppository daily for 3 days • Oral Agent: • Fluconazole 150 mg orally in a single dose Case: • Beth is a 33-year-old single woman who has been in your practice for several years and left a message with your nurse that she has a pruritic vaginal discharge that has persisted for 2 weeks despite her attempts at using an over-the-counter yeast cream. Is it ever appropriate to treat without an examination? • Very frequently, women will attempt to self-diagnose their vaginitis and self-treat with any number of readily available topical or oral agents. • However, the accuracy of self-diagnosis is often worse than is widely assumed. • Given the non-specific nature of vulvovaginal symptoms, patients requesting treatment by telephone should be asked to come in for evaluation, particularly – as in this patient – if she has treated herself with a non-prescription antifungal without success. ** May also depend on the relationship with the patient How do you confirm the diagnosis of candidiasis? What is the treatment? • The diagnosis may be suggested on the basis of history and physical examination, but confirmation requires either • (1) visualization of branched and budding hyphae on KOH wet mount or • (2) a positive culture in a symptomatic woman. • Uncomplicated patients may be treated with either topical clotrimazole or oral fluconazole. • Occasionally, in more severe cases, a second dose or repeated doses of fluconazole will be required. CASE 28 year old housewife is seen by you for a one week history of a frothy, greenish, malodorous vaginal discharge. She also complains of dyspareunia and vaginal irritation. Vaginal pH is 6.5 What is the most likely diagnosis? a.Herpes genitalis b.Trichomonas vaginalis c.Mycoplasma genitalium d.Bacterial vaginosis e.Chlamydia trachomatis Trichomonas Vaginalis -Overview • Almost always sexually transmitted. • In US, an estimated 3.7 million people have the infection. • However, only about 30% develop any symptoms of trichomoniasis. • Associated with adverse pregnancy outcomes. • T. vaginalis infection is associated with two- to threefold increased risk for HIV acquisition. Trichomonas Vaginalis -Signs and Symptoms Patient Reports Physical Exam • Itching, burning, redness or • Classic strawberry cervix in only soreness of the genitals 2% of patients • Discomfort with urination • Diffuse erythema seen in 10- • A change in their vaginal 33% discharge (i.e., thin discharge or increased volume) that can be • Discharge will be noted clear, white, yellowish, or greenish) • *** Can have no symptoms at all Trichomonas Vaginalis -Diagnosis • Vaginal pH greater than 4.5 • Flagella on saline microscopy • Nucleic acid amplification tests NAATs are the most sensitive tests for T.vaginalis and are now considered the gold standard for diagnosis (can use vaginal swab or urine) Trichomonas Vaginalis -Treatment • Partners must be treated! • Metronidazole 2 g orally in a single dose OR • Tinidazole 2 g orally in a single dose • Alternative Regimen • Metronidazole 500 mg orally twice a day for 7 days Treatment Failure • A common reason for treatment failure is reinfection. Therefore, it its critical to assure treatment of all sex partners at the same time. • If treatment failure occurs with metronidazole 2 g orally in a single dose for all partners, treat with metronidazole 500 mg orally twice daily for 7 days or tinidazole 2 g orally single dose. • If treatment failure of either of these regimens, consider retreatment with tinidazole or metronidazole 2 g orally once a day for 5 days. • If repeated treatment failures occur, contact the Division of STD Prevention, CDC, for metronidazole-susceptibility testing (telephone: 404-718-4141, website: www.cdc.gov/std) 21 Case •28 y/o female graduate student is seen for a 5- day history of a thin, greyish-white vaginal discharge associated with vaginal burning and a fishy odor. Whiff test: (+) . Vaginal pH: 5.5 What is the diagnosis? a.Bacterial vaginosis b.Candida vaginitis c.Trichomonas vaginitis d.Mixed infection e.Normal discharge Let’s Focus More on …. Bacterial Vaginosis What percent of women will return with a recurrent BV infection within 12 months after the initial infection? • 20% • 30% • 40% • 50% Bacterial Vaginosis - Overview • Bacterial Vaginosis (BV), formally known as Gardnerella vaginitis, is a common dysbiosis affecting approximately 21 million women in the United States. • BV is often recurrent after treatment with 50% of women having return of symptoms within twelve months. • BV affects 29% of women overall and is more common in Black and Hispanic women with rates of 51% and 32%, respectively. Bacterial Vaginosis - Overview • Some research suggests that it may precipitate preterm labor and has been associated with the development of Pelvic Inflammatory Disease (PID). • USPSTF- has recent EBM question posed on website regarding BV and Pre term labor ----will discuss more later. • BV predisposes women to the acquisition of Sexually Transmitted Infections (STIs), including Human Immunodeficiency Virus (HIV). Bacterial Vaginosis - Pathophysiology • In women with BV the native vaginal flora, hydrogen peroxide producing lactobacilli, that are responsible for maintaining an acidic environment, are replaced with invasive pathogens, G. vaginalis, Prevotella species, and Mobiluncus species. • This promotes a basic pH that sets the environment for BV. • Bacteria is capable of producing a biofilm that provides a matrix for other pathogenic bacteria to cling to as well as making it harder for antibiotic therapy to penetrate and eradicate the infection. Bacterial Vaginosis – Risk Factors • Increased incidence among women: • douche regularly, smoke tobacco , have an IUD in place and have sex with women. • Women that have sex with women have a higher rate of BV and usually both women are affected. • Recurrent BV is higher in women who have multiple sex partners and do not use condoms. • Conversely those that use oral contraceptives such as the pill, have lower rates of BV. • Oral estrogen is thought to have a nurturing effect on the lactobacilli in the vagina perhaps explaining the lower overall rate of BV in women that use oral contraceptives. Most women with BV present with symptoms? • True • False Bacterial Vaginosis – History and Physical Exam • Most women with BV are asymptomatic and unaware they have BV. • Symptomatic women typically present with: • vaginal discharge • odor • sometimes irritation • It is not uncommon for women to report a previous episode of BV within the previous three months to a year. • Physical examination • thin milky discharge • at times a fishy odor is detectable • bimanual exam normal unless another STI is present Bacterial Vaginosis – Diagnosis • Collection of vaginal discharge with a cotton tipped swab from the lateral and posterior vaginal walls for pH measurement and will demonstrate an alkaline environment greater than 4.5. • A saline wet mount slide made from the vaginal secretions will show clue cells.
Load more

Recommended publications
  • The Leucoplakic Vulva: Premalignant Determinants C
    Henry Ford Hospital Medical Journal Volume 11 | Number 3 Article 3 9-1963 The Leucoplakic Vulva: Premalignant Determinants C. Paul Hodgkinson Roy B. P. Patton M. A. Ayers Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Hodgkinson, C. Paul; Patton, Roy B. P.; and Ayers, M. A. (1963) "The Leucoplakic Vulva: Premalignant Determinants," Henry Ford Hospital Medical Bulletin : Vol. 11 : No. 3 , 279-287. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol11/iss3/3 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 11, September, 1963 THE LEUCOPLAKIC VULVA Premalignant Determinants C. PAUL HODGKINSON, M.D.,* ROY B. P. PATTON, M.D., AND M. A. AYERS, M.D.* IN A PAPER proposing to discuss the leucoplakic vulva and any predisposing ten­ dency it may have to the development of squamous cell carcinoma, the term "pre­ malignant" has presumptuous connotations. This is presumptuous because it implies that more is known about cancer and its mode of development than can be supported by facts. What happens in the cell prior to the stage of carcinoma-in-situ is a burning and unsolved question in cancer research. How to detect and appraise the parameters of malignant potential is the essence of meaning connoted by the word "premalignant".
    [Show full text]
  • Ceftazidime for Injection) PHARMACY BULK PACKAGE – NOT for DIRECT INFUSION
    PRESCRIBING INFORMATION FORTAZ® (ceftazidime for injection) PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4­ thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1­ azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure: The molecular formula is C22H32N6O12S2, representing a molecular weight of 636.6. FORTAZ is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. The Pharmacy Bulk Package vial contains 709 mg of sodium carbonate. The sodium content is approximately 54 mg (2.3mEq) per gram of ceftazidime. FORTAZ in sterile crystalline form is supplied in Pharmacy Bulk Packages equivalent to 6g of anhydrous ceftazidime. The Pharmacy Bulk Package bottle is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous use. THE PHARMACY BULK PACKAGE IS NOT FOR DIRECT INFUSION, FURTHER DILUTION IS REQUIRED BEFORE USE.
    [Show full text]
  • The Relations Between Anemia and Female Adolescent's Dysmenorrhea
    Universitas Ahmad Dahlan International Conference on Public Health The Relations Between Anemia and Female Adolescent’s Dysmenorrhea Paramitha Amelia Kusumawardani, Cholifah Diploma Program of Midwifery, Health Science Faculty , University of Muhammadiyah Sidoarjo Article Info ABSTRACT Keyword: Dysmenorrhea described as painful cramps in the lower abdomen that Anemia, occur during menstruation and the infection indications, pelvic disease Dysmenorrhea, moreover in the severe cases it caused fainted. The women who Female adolescents. complained dysmenorrhea problems mostly are who experience menstruation at any age. That means there is no limits age and usually dysmenorrhea often occur with dizziness, cold sweating, even fainted. In some countries the dysmenorrhea problem happens quite high as happened in the United States found 60-91% while in Indonesia amounted to 64.25%. as many as 45-75% of female adolescent experienced dysmenorrhea with the chronic or severe pain that effected to their everyday activities The number of teenagers who experience dysmenorrhea is due to high cases of anemia, irregular exercise, and lack of knowledge of nutritional status. In the previous study there are 85% of female adolescent experience dysmenorrhea. The method of this study is a correlational method with cross sectional approach. The data collecting method examining Hb levels. The population and sample of this study was 40 female adolescent The result showed that the female adolescent who had dysmenorrhea with anemia was 26 (92.4%). From the calculation by Exact Fisher the correlation between anemia and dysmenorrhea cases among female adolescent P <0.05 and p = 0.003, there was significant correlation between adolescent’s dysmenorrhea. Based on the result of statistic analysis, it can be concluded that the anemia can be categorized as one of dysmenorrhea causes.
    [Show full text]
  • Endometritis Caused by Chlamydia Trachomatis
    Br J Vener Dis 1981; 57:191-5 Endometritis caused by Chlamydia trachomatis P-A MARDH,* B R M0LLER,t H J INGERSELV,* E NUSSLER,* L WESTROM,§ AND P W0LNER-HANSSEN§ From the *Institute of Medical Microbiology, University of Lund, Sweden; the tlnstitute of Medical Microbiology, University of Aarhus, Denmark; the *Department of Obstetrics and Gynaecology, Municipal Hospital, Aarhus, Denmark; and the §Department of Obstetrics and Gynaecology, University Hospital, Lund, Sweden SUMMARY Chlamydia trachomatis was found to be the aetiological agent of endometritis in three women with concomitant signs of salpingitis. All patients developed a significant antibody response to the organism. Chlamydia were recovered from aspirated uterine contents of two patients and darkfield examination of histological sections showed chlamydial inclusions in endometrial cells in one patient. Thus, C trachomatis can be recovered from the endometrium of patients in whom the cervical culture result is negative. In one patient curettage showed endometritis with a characteristic plasma-cell infiltration. The occurrence of chlamydial endometritis may explain why irregular bleeding is a common finding in patients with salpingitis. It also suggests a canalicular spread of chlamydia from the cervix to the Fallopian tubes. Introduction hominis and Ureaplasma urealyticum by cotton- tipped wooden sticks. Specimens for the isolation of Chlamydia trachomatis has been associated with N gonorrhoeae from the cervix and rectum were cervicitis' and salpingitis,2 and perihepatitis may collected with cotton-tipped wooden swabs treated occur in women with chlamydial genital infection.3 with charcoal. Salpingitis caused by chlamydia4 and gonococci5 are histologically similar. Gonococcal salpingitis is an Endometrial contents endosalpingitis and the infection spreads to the For the collection of end6metrial contents, a plastic Fallopian tubes from the cervix via the tube (armoured with a mandrin) was introduced endometrium.5 Experimental salpingitis in monkeys through the cervical canal.
    [Show full text]
  • Vaginitis and Abnormal Vaginal Bleeding
    UCSF Family Medicine Board Review 2013 Vaginitis and Abnormal • There are no relevant financial relationships with any commercial Vaginal Bleeding interests to disclose Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine [email protected] Vulvovaginal Symptoms: CDC 2010: Trichomoniasis Differential Diagnosis Screening and Testing Category Condition • Screening indications – Infections Vaginal trichomoniasis (VT) HIV positive women: annually – Bacterial vaginosis (BV) Consider if “at risk”: new/multiple sex partners, history of STI, inconsistent condom use, sex work, IDU Vulvovaginal candidiasis (VVC) • Newer assays Skin Conditions Fungal vulvitis (candida, tinea) – Rapid antigen test: sensitivity, specificity vs. wet mount Contact dermatitis (irritant, allergic) – Aptima TMA T. vaginalis Analyte Specific Reagent (ASR) Vulvar dermatoses (LS, LP, LSC) • Other testing situations – Vulvar intraepithelial neoplasia (VIN) Suspect trich but NaCl slide neg culture or newer assays – Psychogenic Physiologic, psychogenic Pap with trich confirm if low risk • Consider retesting 3 months after treatment Trichomoniasis: Laboratory Tests CDC 2010: Vaginal Trichomoniasis Treatment Test Sensitivity Specificity Cost Comment Aptima TMA +4 (98%) +3 (98%) $$$ NAAT (like GC/Ct) • Recommended regimen Culture +3 (83%) +4 (100%) $$$ Not in most labs – Metronidazole 2 grams PO single dose Point of care – Tinidazole 2 grams PO single dose •Affirm VP III +3 +4 $$$ DNA probe • Alternative regimen (preferred for HIV infected
    [Show full text]
  • Localised Provoked Vestibulodynia (Vulvodynia): Assessment and Management
    FOCUS Localised provoked vestibulodynia (vulvodynia): assessment and management Helen Henzell, Karen Berzins Background hronic vulvar pain (pain lasting more than 3–6 months, but often years) is common. It is estimated to affect 4–8% of Vulvodynia is a chronic vulvar pain condition. Localised C women at any one time and 10–20% in their lifetime.1–3 provoked vestibulodynia (LPV) is the most common subset Little attention has been paid to the teaching of this condition of vulvodynia, the hallmark symptom being pain on vaginal so medical practitioners may not recognise the symptoms, and penetration. Young women are predominantly affected. LPV diagnosis is often delayed.2 Community awareness is low, but is a hidden condition that often results in distress and shame, increasing with media attention. Women can be confused by the is frequently unrecognised, and women usually see a number symptoms and not know how to discuss vulvar pain. The onus is of health professionals before being diagnosed, which adds to on medical practitioners to enquire about vulvar pain, particularly their distress and confusion. pain with sex, when taking a sexual or reproductive health history. Objective Vulvodynia The aim of this article is to inform health providers about the Vulvodynia is defined by the International Society for the Study assessment and management of LPV. of Vulvovaginal Disease (ISSVD) as ‘chronic vulvar discomfort, most often described as burning pain, occurring in the absence Discussion of relevant findings or a specific, clinically identifiable, neurologic 4 Diagnosis is based on history. Examination is used to support disorder’. It is diagnosed when other causes of vulvar pain have the diagnosis.
    [Show full text]
  • Effect of Educational Program on Vulvitis Prevention Among Nursing Students
    American Journal of Nursing Science 2018; 7(6): 254-267 http://www.sciencepublishinggroup.com/j/ajns doi: 10.11648/j.ajns.20180706.19 ISSN: 2328-5745 (Print); ISSN: 2328-5753 (Online) Effect of Educational Program on Vulvitis Prevention Among Nursing Students Somaya Ouda Abd EL-Menim 1, Huda Abdalla Moursi 2, Ahlam Elahmady Mohamed Sarhan 2 1Obstetric and Woman Health Nursing, Faculty of Nursing, Benha University, Benha, Egypt 2Community Health Nursing, Benha University, Benha, Egypt Email address: To cite this article: Somaya Ouda Abd EL-Menim, Huda Abdalla Moursi, Ahlam Elahmady Mohamed Sarhan. Effect of Educational Program on Vulvitis Prevention among Nursing Students. American Journal of Nursing Science . Vol. 7, No. 6, 2018, pp. 254-267. doi: 10.11648/j.ajns.20180706.19 Received : November 7, 2018; Accepted : November 23, 2018; Published : January 2, 2019 Abstract: The aim of this study was to evaluate the effect of educational program on vulvitis prevention among nursing students Research design: A quasi-experimental design was utilized. Setting: This study was conducted at Faculty of Nursing, Benha University. Sample: convenient sample included two hundred and fifty nursing students female all enrolled in first academic years. Tools of data collection1) a structured interviewing sheet to collect data about socio-demographic characteristics, menstrual and gynecological history and knowledge of nursing students regarding vulvitis 2) reported practices assessment 3) modified likert scale for students' attitude regarding vulvitis. Results: there were general improvements regarding students' knowledge, attitude and practice regarding prevention of vulvitis with highly significant (P ≤ 0.001) difference after educational Program. The mother was the main sources of knowledge to students (60%).
    [Show full text]
  • 209627Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209627Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review Reviewers of Multi-Disciplinary Review and Evaluation SECTIONS OFFICE/ AUTHORED/ ACKNOWLEDGED/ DISCIPLINE REVIEWER DIVISION APPROVED Mark Seggel, Ph.D. OPQ/ONDP/DNDP2 Authored: Section 4.2 Digitally signed by Mark R. Seggel -S CMC Lead DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mark R. Signature: Mark R. Seggel -S Seggel -S, 0.9.2342.19200300.100.1.1=1300071539 Date: 2018.08.08 16:29:15 -04'00' Frederic Moulin, DVM, PhD OND/ODE3/DBRUP Authored: Section 5 Pharmacology/ Digitally signed by Frederic Moulin -S Toxicology DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Reviewer Signature: Frederic Moulin -S 0.9.2342.19200300.100.1.1=2001708658, cn=Frederic Moulin -S Date: 2018.08.08 15:26:57 -04'00' Kimberly Hatfield, PhD OND/ODE3/DBRUP Approved: Section 5 Pharmacology/ Toxicology Digitally signed by Kimberly P. Hatfield -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Team Leader Signature: Kimberly P. Hatfield -S 0.9.2342.19200300.100.1.1=1300387215, cn=Kimberly P. Hatfield -S Date: 2018.08.08 14:56:10 -04'00' Li Li, Ph.D. OCP/DCP3 Authored: Sections 6 and 17.3 Clinical Pharmacology Dig ta ly signed by Li Li S DN c=US o=U S Government ou=HHS ou=FDA ou=People Reviewer cn=Li Li S Signature: Li Li -S 0 9 2342 19200300 100 1 1=20005 08577 Date 2018 08 08 15 39 23 04'00' Doanh Tran, Ph.D.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Vaginal Delivery System
    (19) & (11) EP 2 062 568 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 9/00 (2006.01) (21) Application number: 07397042.8 (22) Date of filing: 22.11.2007 (84) Designated Contracting States: • Hanes, Vladimir AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tarrytown, NY 10591 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Keinänen, Antti SI SK TR 20540 Turku (FI) Designated Extension States: • Holmberg, Svante AL BA HR MK RS 20900 Turku (FI) • Nikander, Hannu (71) Applicant: Bayer Schering Pharma Oy 21330 Paattinen (FI) 20210 Turku (FI) (74) Representative: Matilainen, Mirja Helena et al (72) Inventors: Oy Jalo Ant-Wuorinen AB, • Talling, Christine Iso Roobertinkatu 4-6 A 20610 Turku (FI) 00120 Helsinki (FI) (54) Vaginal delivery system (57) The present invention is related to an intravag- brane (3) encasing the core, said core and membrane inal delivery system for the controlled release of a pro- essentially consisting of a same or different polymer com- gestogen and an estrogen, comprising additionally a position, wherein at cast one of the cores comprises a therapeutically active or a health-promoting substance progestogen or a mixture of a progestogen and an es- (1) capable of giving and/or enhancing the protection trogen, and another core may comprise an estrogen or against bacterial and fungal infections, and/or enhancing a progestogen, and wherein the membrane or the surface the protection against sexually transmitted diseases. The of the membrane or at least one of the cores comprises delivery system consists of one or more compartments said therapeutically active or a health-promoting sub- (2,4,5), one of each comprising a core (7) and a mem- stance.
    [Show full text]
  • NPTC-Formulary Brief Acne
    Indian Health Service National Pharmacy and Therapeutics Committee Formulary Brief: Treatment of Acne vulgaris -January 2020- Background: The Indian Health Service (IHS) National Pharmacy and Therapeutics Committee (NPTC) reviewed the medical management of acne vulgaris at their January 2020 meeting. This review included topical therapies (retinoids, antibiotics, bactericidal and other anti-comedonal or anti-inflammatory agents) and oral therapies (antibiotics, isotretinoin, oral contraceptives, antiandrogens). Topical clindamycin, topical tretinoin, spironolactone, and combined estrogen-containing oral contraceptives are currently on the IHS National Core Formulary (NCF). Following clinical review, pharmacoeconomic evaluation and internal deliberation, the NPTC voted to ADD (1.) benzoyl peroxide (any topical formulation) and REPLACE topical clindamycin with (2.) combination clindamycin and benzoyl peroxide gel to the NCF. Discussion: Acne is the most common skin disorder in the United States (US), affecting 40-50 million persons of all ages. It can have significant sequelae from physical scarring, persistent hyperpigmentation, and psychological issues. Small studies focused on acne among American Indian/Alaska Native (AI/AN) populations suggest that the prevalence of acne is similar to other racial/ethnic groups in the US, but that the sequelae of scarring is significantly higher (55% in AI/AN vs. 3% among US white populations) and access to specialty care services is disproportionately low1. Acne is a chronic inflammatory disease of the pilosebaceous unit involving increased sebum production by sebaceous glands, hyperkeratinization of the follicle, colonization of the follicle by Propionobacterium acnes, and an inflammatory reaction. Acne is manifested with both non-inflammatory (open and closed comedones) and inflammatory lesions (papules, pustules, and nodules). Inflammatory acne is graded as mild, moderate, or severe based on the frequency of the various inflammatory lesions.
    [Show full text]
  • Prioritization of Health Services
    PRIORITIZATION OF HEALTH SERVICES A Report to the Governor and the 74th Oregon Legislative Assembly Oregon Health Services Commission Office for Oregon Health Policy and Research Department of Administrative Services 2007 TABLE OF CONTENTS List of Figures . iii Health Services Commission and Staff . .v Acknowledgments . .vii Executive Summary . ix CHAPTER ONE: A HISTORY OF HEALTH SERVICES PRIORITIZATION UNDER THE OREGON HEALTH PLAN Enabling Legislatiion . 3 Early Prioritization Efforts . 3 Gaining Waiver Approval . 5 Impact . 6 CHAPTER TWO: PRIORITIZATION OF HEALTH SERVICES FOR 2008-09 Charge to the Health Services Commission . .. 25 Biennial Review of the Prioritized List . 26 A New Prioritization Methodology . 26 Public Input . 36 Next Steps . 36 Interim Modifications to the Prioritized List . 37 Technical Changes . 38 Advancements in Medical Technology . .42 CHAPTER THREE: CLARIFICATIONS TO THE PRIORITIZED LIST OF HEALTH SERVICES Practice Guidelines . 47 Age-Related Macular Degeneration (AMD) . 47 Chronic Anal Fissure . 48 Comfort Care . 48 Complicated Hernias . 49 Diagnostic Services Not Appearing on the Prioritized List . 49 Non-Prenatal Genetic Testing . 49 Tuberculosis Blood Test . 51 Early Childhood Mental Health . 52 Adjustment Reactions In Early Childhood . 52 Attention Deficit and Hyperactivity Disorders in Early Childhood . 53 Disruptive Behavior Disorders In Early Childhood . 54 Mental Health Problems In Early Childhood Related To Neglect Or Abuse . 54 Mood Disorders in Early Childhood . 55 Erythropoietin . 55 Mastocytosis . 56 Obesity . 56 Bariatric Surgery . 56 Non-Surgical Management of Obesity . 58 PET Scans . 58 Prenatal Screening for Down Syndrome . 59 Prophylactic Breast Removal . 59 Psoriasis . 59 Reabilitative Therapies . 60 i TABLE OF CONTENTS (Cont’d) CHAPTER THREE: CLARIFICATIONS TO THE PRIORITIZED LIST OF HEALTH SERVICES (CONT’D) Practice Guidelines (Cont’d) Sinus Surgery .
    [Show full text]